FDA seeks input on social media regulation

Share this article:
Will the FDA hearings on social media, which kicked off today, result in guidance specific to online media? That's the question on the minds of digital gurus converging on the capitol for two days of presentations on using social media in drug and device marketing.

The FDA said it will draw on participants' suggestions to “help guide policy decisions.” Some say this is overdue.

Addressing delegates at the PRWeek Next Conference at the Waldorf Astoria in New York on the eve of the FDA hearings, Ray Kerins VP, worldwide communications, Pfizer, said guidelines are “sorely needed.”

Indeed, as Twitter and Facebook rapidly emerge as channels to reach patients and build online communities, drug company interactive managers are tempted but understandably reticent to use Web 2.0 tools, without clear rules on handling risk communication and adverse-event reporting.

Last March FDA issued untitled letters to 14 companies for omitting fair balance in sponsored links on search engines. The letters seemed to suggest that the traditional “one-click” rule—in which risk information is available on a landing page a single click away—does not suffice as does turning the page to get such information in a print ad.

Kerins said any guidance is better than none and that the FDA is trying to do the right thing. “Nobody should point the finger at the FDA and say this is their fault—because it's not.”

MM&M's senior editor, Matthew Arnold, is attending the hearings and will offer his insight and commentary in a roundup following each of the two days' testimony.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?